193 related articles for article (PubMed ID: 26216709)
21. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
24. [Pegvisomant decreases growth hormone to nothing].
Krankenpfl J; 2004; 42(1-2):16-7. PubMed ID: 15116768
[No Abstract] [Full Text] [Related]
25. GH receptor antagonist: mechanism of action and clinical utility.
Surya SK; Barkan AL
Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
[TBL] [Abstract][Full Text] [Related]
26. Pegvisomant (Somavert) for acromegaly.
Med Lett Drugs Ther; 2003 Jul; 45(1160):55-6. PubMed ID: 12840714
[No Abstract] [Full Text] [Related]
27. [Growth hormone receptor antagonists: potential indications].
Muller AF; Janssen JA; de Herder WW; van der Lely AJ
Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
[TBL] [Abstract][Full Text] [Related]
28. The nuclear-localized GHR is involved in the cell proliferation of gastric cancer, and pegvisomant may be an important potential drug to inhibit the proliferation of gastric cancer cells.
Meng Y; Zhou B; Pei Z; Chen Y; Chang D
Biochem Cell Biol; 2022 Apr; 100(2):125-135. PubMed ID: 35061546
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
30. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
31. Growth hormone regulates neuroendocrine responses to weight loss via AgRP neurons.
Furigo IC; Teixeira PDS; de Souza GO; Couto GCL; Romero GG; Perelló M; Frazão R; Elias LL; Metzger M; List EO; Kopchick JJ; Donato J
Nat Commun; 2019 Feb; 10(1):662. PubMed ID: 30737388
[TBL] [Abstract][Full Text] [Related]
32. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
33. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
34. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone excess and the development of growth hormone receptor antagonists.
Higham CE; Trainer PJ
Exp Physiol; 2008 Nov; 93(11):1157-69. PubMed ID: 18617577
[TBL] [Abstract][Full Text] [Related]
36. Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-deficient (lit/lit) mice and transgenic mice that overexpress bovine GH (bGH) or a bGH antagonist.
Iida K; Del Rincon JP; Kim DS; Itoh E; Nass R; Coschigano KT; Kopchick JJ; Thorner MO
Endocrinology; 2004 Apr; 145(4):1564-70. PubMed ID: 14726438
[TBL] [Abstract][Full Text] [Related]
37. Clinical review 166: Growth hormone receptor antagonists.
Muller AF; Kopchick JJ; Flyvbjerg A; van der Lely AJ
J Clin Endocrinol Metab; 2004 Apr; 89(4):1503-11. PubMed ID: 15070905
[No Abstract] [Full Text] [Related]
38. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
40. Growth hormone receptor modulators.
Birzniece V; Sata A; Ho KK
Rev Endocr Metab Disord; 2009 Jun; 10(2):145-56. PubMed ID: 18622706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]